Home Blog
The new deal expands upon a years-long cooperative partnership that has included the development of the SOPHiA Hereditary Cancer Solution—an in vitro diagnostic (IVD) launched in 2016—which predicts the genetic susceptibility and risk for patients of developing hereditary breast and ovarian cancer.
Nurse helping patient in hospital bed take a drink
The drink targets small DNA elements called plasmids that carry antibiotic resistance genes. By preventing these plasmids from replicating, the antibiotic resistance genes are displaced, effectively re-sensitizing the bacteria to antibiotics.
Professor Susan Clark and colleagues at the Garvan Institute of Medical Research showed that the 3D structure of DNA is 'rewired' in hormone resistant ER+ breast cancers, altering normal gene activation and repression in the cells.
The two companies will look to develop a kitted NGS solution for the identification of biomarkers using blood samples collected from patients enrolled in clinical trials.
Dendritic cell and T-lymphocytes, illustration
The team developed a computational approach to estimate corrected TMB values for each tumor by simulating 20,000 tumors with various levels of TMB and sequencing coverage using information from the Cancer Genome Atlas to generate a correction factor for each simulated tumor based on its purity.
Genetic testing concept, DNA icon, medical doctor, isolated on white
Breakthrough device designation is designed to provide patients and healthcare providers with timely access to medical devices by speeding up their development, assessment, and review, while preserving FDA standards.
Illustration of a cancer cell
Investigators discovered that MYC and TWIST1, two transcription factors, together elicit a cytokinome whose signaling enabled crosstalk between cancer cells and host macrophages—driving tumor progression.
Fabric Genomics is partnering with data management company ITTM to provide secure genomic data hosting capabilities for European customers. (Source: iStock/© evryka23)
Children’s Hospital of Philadelphia researchers compared the sequence data of more than 100,000 people of European ancestry and found copy number variant (CNV) associations in four major disease categories: autoimmune, cardio-metabolic, oncologic, and neurological/psychiatric diseases.
ersonal Genome Diagnostics (PGDx) said today that its 500+ gene pan-cancer tumor profiling tissue assay is being used by Merck & Co. in a Phase II clinical trial designed to assess patient response to a dual biomarker-directed precision oncology combination therapy in patients with previously untreated advanced non-small cell lung cancer (NSCLC).
The deals with each partner will initially focus on the KRAS G12C mutation as found in non-small cell lung cancer (NSCLC), which accounts for approximately 13% of all NSCLC cases.
Once Genexus is validated, the automated platform could help accelerate access to next-generation sequencing (NGS) testing for clinical trials through LabCorp’s specialty and drug development central laboratories.
Scroll Up